BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23966410)

  • 1. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge.
    Klein K; Veazey RS; Warrier R; Hraber P; Doyle-Meyers LA; Buffa V; Liao HX; Haynes BF; Shaw GM; Shattock RJ
    J Virol; 2013 Nov; 87(21):11604-16. PubMed ID: 23966410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
    Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
    Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies.
    Mascola JR; Lewis MG; VanCott TC; Stiegler G; Katinger H; Seaman M; Beaudry K; Barouch DH; Korioth-Schmitz B; Krivulka G; Sambor A; Welcher B; Douek DC; Montefiori DC; Shiver JW; Poignard P; Burton DR; Letvin NL
    J Virol; 2003 Oct; 77(19):10348-56. PubMed ID: 12970419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
    Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
    Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
    EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
    J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.
    Moog C; Dereuddre-Bosquet N; Teillaud JL; Biedma ME; Holl V; Van Ham G; Heyndrickx L; Van Dorsselaer A; Katinger D; Vcelar B; Zolla-Pazner S; Mangeot I; Kelly C; Shattock RJ; Le Grand R
    Mucosal Immunol; 2014 Jan; 7(1):46-56. PubMed ID: 23591718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
    Moldt B; Shibata-Koyama M; Rakasz EG; Schultz N; Kanda Y; Dunlop DC; Finstad SL; Jin C; Landucci G; Alpert MD; Dugast AS; Parren PW; Nimmerjahn F; Evans DT; Alter G; Forthal DN; Schmitz JE; Iida S; Poignard P; Watkins DI; Hessell AJ; Burton DR
    J Virol; 2012 Jun; 86(11):6189-96. PubMed ID: 22457527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.
    Wolbank S; Kunert R; Stiegler G; Katinger H
    J Virol; 2003 Apr; 77(7):4095-103. PubMed ID: 12634368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
    Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
    Gautam R; Nishimura Y; Pegu A; Nason MC; Klein F; Gazumyan A; Golijanin J; Buckler-White A; Sadjadpour R; Wang K; Mankoff Z; Schmidt SD; Lifson JD; Mascola JR; Nussenzweig MC; Martin MA
    Nature; 2016 May; 533(7601):105-109. PubMed ID: 27120156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.
    Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
    J Virol; 2002 Mar; 76(5):2123-30. PubMed ID: 11836389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    Mascola JR; Lewis MG; Stiegler G; Harris D; VanCott TC; Hayes D; Louder MK; Brown CR; Sapan CV; Frankel SS; Lu Y; Robb ML; Katinger H; Birx DL
    J Virol; 1999 May; 73(5):4009-18. PubMed ID: 10196297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus.
    Liu J; Ghneim K; Sok D; Bosche WJ; Li Y; Chipriano E; Berkemeier B; Oswald K; Borducchi E; Cabral C; Peter L; Brinkman A; Shetty M; Jimenez J; Mondesir J; Lee B; Giglio P; Chandrashekar A; Abbink P; Colantonio A; Gittens C; Baker C; Wagner W; Lewis MG; Li W; Sekaly RP; Lifson JD; Burton DR; Barouch DH
    Science; 2016 Sep; 353(6303):1045-1049. PubMed ID: 27540005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges.
    Gong S; Lakhashe SK; Hariraju D; Scinto H; Lanzavecchia A; Cameroni E; Corti D; Ratcliffe SJ; Rogers KA; Xiao P; Fontenot J; Villinger F; Ruprecht RM
    Front Immunol; 2021; 12():705592. PubMed ID: 34413855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.